Medicaments to combat autoimmune diseases

Details Medicaments to combat autoimmune diseases Medicaments to combat autoimmune diseases

1995-06-07

1997-10-21

Criares, Theodore J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

514378, 514627, A61K 31275, A61K 3142, A61K 3116

Patent

active

056797095

ABSTRACT:
A pharmaceutical composition for use in the treatment of chronic Graft-versus-host diseases as well as autoimmune diseases, in particular for the treatment of systemic lupus erythematosus containing as an active ingredient at least one compound of the formula 1 or 2 ##STR1## the latter being present per se or in the form of a physiologically tolerable salt.
The invention also relates to a dosage unit form of said pharmaceutical composition and a method of treating chronic Graft-versus host diseases as well as autoimmune diseases, in particular systemic lupus erythematosus.

REFERENCES:
patent: 4061767 (1977-12-01), Ertel et al.
patent: 4284786 (1981-08-01), Kammerer et al.
patent: 4343796 (1982-08-01), Groen
patent: 4435387 (1984-03-01), Schaub et al.
patent: 4435407 (1984-03-01), Walker
patent: 4636513 (1987-01-01), Kammerer et al.
patent: 4965276 (1990-10-01), Bartlett et al.
Ackermann, N.R., et al., "The Effects of D-penicilliname in the MRL/1 Mouse," Adv. Infl. Res., 7: 277-286 (1984).
Bartlett, R. R., et al., "Immunopharmacological Profile of a Novel Isoxazol Derivative, HWA 486, with Potential Antirheumatic Activity--I. Diesease Modifying Action on Adjuvant Arthritis of the Rat," Intl. J. Immunopharmac., 7(1): 7-18 (1985).
Bartlett, R. R., "Immunopharmacological Profile of HWA 486, a Novel Isoxazol Derivative--II. In vivo Immunomodulating Effects Differ From Those of Cyclophosphamide, Prednisolone, or Cyclosporin A," Intl. J. Immunopharmac., 8(2): 199-204 (1986).
Burlingame, M., et al., "Treatment of Systemic Lupus Erythematosus," Drug Intelligence and Clinical Pharmacy, 22: 283-289 (1988).
Gleichmann, E., et al., "A Systemic Lupus Erythematosus (SLE)-like Disease in Mice Induced by Abnormal T-B Cell Cooperation. Preferential Formation of Autoantibodies Characteristic of SLE," Eur. J. Immunol., 12: 152-159 (1982).
Pisetsky, D., "Systemic Lupus Erythematosus," Adv. Rhreum., Medical Clinics of North America, 70(2): 337-353 (1986).
Popovic, S., et al., "The Use of the Murine Chronic Graft vs. Host (CGVH) Disease, A Model for Systemic Lupus Erythematosus (SLE), for Drug Discovery," Agents and Actions, 21(3/4): 284-286 (1987).
Stecher, V. J., et al., "Disease Modifying Anti-Rheumatic Drugs," Annual Reports in Medicinal Chemistry, 18: 171-179 (1983).
D. J. Weatherall et al., Oxford Textbook of Medicine, Second Edition, eds. vol. 2, pp. 16.20-16.28 and 21.211-21.216 (1987).

Affiliated with

Also associated with

Rating

Medicaments to combat autoimmune diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medicaments to combat autoimmune diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicaments to combat autoimmune diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1007198